Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Teva
Chinese Patent Office
McKesson
US Army
AstraZeneca
Mallinckrodt
Chubb
Colorcon

Generated: May 28, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,617,595

« Back to Dashboard

Which drugs does patent 8,617,595 protect, and when does it expire?

Patent 8,617,595 protects TEKTURNA and is included in one NDA.

Protection for TEKTURNA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-nine patent family members in twenty-two countries.
Summary for Patent: 8,617,595
Title:Galenic formulations of organic compounds
Abstract: The present invention relates to a solid oral dosage form comprising a therapeutically effective amount of aliskiren or a pharmaceutically acceptable salt thereof, and wherein the active ingredient is present in an amount of more than 46% by weight based on the total weight of the oral dosage form.
Inventor(s): Rigassi-Dietrich; Petra G (Therwil, CH), Schmid; Martin (Wettingen, CH)
Assignee: Novartis AG (Basel, CH)
Application Number:10/590,398
Patent Claim Types:
see list of patent claims
Compound; Dosage form; Use; Formulation; Process;

Drugs Protected by US Patent 8,617,595

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Noden Pharma TEKTURNA aliskiren hemifumarate TABLET;ORAL 021985-001 Mar 5, 2007 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Noden Pharma TEKTURNA aliskiren hemifumarate TABLET;ORAL 021985-002 Mar 5, 2007 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,617,595

PCT Information
PCT FiledMarch 16, 2005PCT Application Number:PCT/EP2005/002798
PCT Publication Date:September 29, 2005PCT Publication Number: WO2005/089729

Non-Orange Book US Patents Family Members for Patent 8,617,595

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,683,054 Galenic formulations of organic compounds ➤ Sign Up
8,007,824 Galenic formulations of organic compounds ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
QuintilesIMS
Express Scripts
Accenture
Baxter
AstraZeneca
Citi
Colorcon
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.